2016-06-16T15:29:52-07:00 2015-12-31 Regalia & Associates CPAs 103 Town Country Dr Ste K Danville CA 94526 990 2015-01-01 651230251 THE CANARY FUND DBA CANARY FOUNDATION CANA 6506463200 805 Veterans Blvd Redwood City CA 94063 Ronica Smucker Exec Director 2016-06-16 true Douglas W Regalia P00186389 9253140390 2015 2016-09-27 15:27:22Z X Don Listwin 805 Veterans Blvd Suite 301 Redwood City CA 94063 4266744 false false X www.canaryfoundation.org X 2004 CA Canary Foundation is the world's first non-profit organization dedicated solely to the funding, discovery and development of tests for early cancer detection. 6 5 9 0 9195967 2958235 0 1888 -4468 59674 372689 9257529 3326456 1138437 5701358 0 629137 653054 0 541785 422099 601276 2189673 6955688 7067856 -3629232 13709562 10651818 14166699 14481988 -457137 -3830170 X Canary Foundation is a public charity exempt from U.S. federal income tax under Section 501(c)(3) of the Internal Revenue Code in the United States. Canary Foundation of Canada is a Public Foundation registered with the Canada Revenue Agency; Business Number 82906 8550 RROOO1.The Canary Foundation has assembled teams of cancer researchers recognized by their peers as leaders in their disciplines from across multiple institutions and disciplines to attack the problem of early detection in a new, collaborative, action-oriented manner with the foremost objective of translating research into clinical applications. Canary differentiators include: * Dedication to early detection * Leaders in collaborative science * Focused and managed research * Best-in-class talent * 100% of donations goes to researchOne of the first decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers pro false false 6000378 5701358 Canary Scientific ProgramsCanary is the worlds only non-profit focused solely on early cancer detection. We have multidisciplinary science teams focused on blood-based biomarkers or biological fingerprints that show the presence or progress of disease. Were pairing those biomarkers with advanced imaging technologies that will help us visualize a cancer type with more sensitivity and specificity. Our clinical programs cover tumors across five cancer types: breast, lung, ovarian, pancreas, and prostate. And to further ensure our success, we funded the Canary Center at Stanford for Cancer Early Detection, a world-class facility that hopes to save lives through early detection. CANARY BREAST CANCER PROGRAMThe Breast Cancer Program is working to improve early detection of potentially lethal breast cancer by identifying biomarkers that complement existing imaging methods and by developing new imaging alternatives. The Breast Cancer Program is focused at Stanford and combines expertise in breast cancer care, in breast imaging, and in studying proteomic and gene expression changes in the body in response to disease. Additional work aims to identify biomarkers that distinguish women with cancer from those with benign conditions (such as a cyst). These biomarkers would potentially reduce the number of unnecessary invasive follow-up tests and enhance the interpretation of mammographic images for early detection of breast cancer. New imaging approaches may provide a more sensitive and more accurate approach for the detection of breast cancers. We are testing several imaging alternatives, including a new PET imaging agent, enhanced ultrasound using targeted microbubbles, and photoacoustic imaging, for their ability to identify breast cancer early and to better distinguish cancer and benign conditions.CANARY OVARIAN CANCER PROGRAMThe goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. Our vision is of a two-stage screening strategy, consisting of a simple blood test followed by a molecular imaging test. Development of blood and imaging tests follows a similar roadmap; both include (continued on Schedule O) 6000378 true true false false false false false false false false true false false false false true true false false false true true false false true false false true false true false false false false false false false false false false false true false false false false false false false false false true 6 0 true 9 true false false true OC false false true true false false 0 false false false false false false false false false false X 6 5 true false false false false false false true true false false true true true true true true true true false CA X X Theresa McCann Operations Mgr 6506463200 805 Veterans Blvd Suite 301 Redwood City CA 94063 Don Listwin Founder & CEO 8.00 0.00 X X 0 0 0 Rob Lynch Director 4.00 0.00 X 0 0 0 Dale Jantzen Director 4.00 0.00 X 0 0 0 Michael Ball Director 4.00 0.00 X 0 0 0 Kevin Kennedy Chair/Treasurer 4.00 0.00 X 0 0 0 Hilary Valentine Director 4.00 0.00 X 0 0 0 Ronica Smucker Exec Director 40.00 0.00 X 220000 0 29631 Therese Quinlan Snr Developmt Dir 40.00 0.00 X 144000 0 15503 364000 45134 2 false true false 0 37300 2920935 446096 2958235 0 -3222 -3222 0 0 0 1246 -1246 -1246 -1246 1311731 37300 939042 372689 0 0 0 3326456 -4468 5666844 5666844 0 34514 34514 0 220000 52026 73419 94555 0 184344 25157 68223 90964 50154 9574 17569 23011 143325 27359 50207 65759 55231 10543 19347 25341 0 0 32355 32355 0 0 0 19579 19579 178223 178223 23112 19599 3513 1868 1868 0 54804 19724 35080 0 0 104473 104473 0 0 7009 288 6721 11557 11557 Outside services 57520 16620 40900 Travel, hotels, meals 51967 49876 2091 Website, internet, relations 27740 13389 14351 Bank and credit card charges 10389 10389 20680 15512 5168 6955688 6000378 413525 541785 444214 493669 744338 1308135 12459728 8725427 0 0 0 0 0 43336 88580 53977 17970 17946 36007 0 0 0 0 0 13709562 10651818 56958 46760 14109741 14435228 14166699 14481988 X -12904422 -12548514 12447285 8718344 -457137 -3830170 13709562 10651818 X -3629232 256199 X false true X true false X 11328418 9959117 1260385 8499658 2943295 33990873 0 0 11328418 9959117 1260385 8499658 2943295 33990873 14123921 19866952 -9512 1050 3541 3511 -3222 -4632 0 -1728 -1857 -40548 -1734 -1246 -47113 33939128 0.58540 0.61170 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 26863 14287 12576 27114 3683 23431 36007 X 4521697 1195241 1195241 3326456 3326456 7894730 939042 939042 6955688 6955688 Part X : FIN48 Footnote Income TaxesFinancial statement presentation follows the recommendations of ASC 740, Income Taxes. Under ASC 740, the Fund is required to report information regarding its exposure to various tax positions taken by the Fund and requires a two-step process that separates recognition from measurement. The first step is determining whether a tax position has met the recognition threshold; the second step is measuring a tax position that meets the recognition threshold. Management believes that the Fund has adequately evaluated its current tax positions and has concluded that as of December 31, 2015, the Fund does not have any uncertain tax positions for which a reserve or an accrual for a tax liability would be necessary.The Fund has received notification from the Internal Revenue Service and the State of California that it qualifies for tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and Section 23701d of the California Revenue and Taxation Code. The exemptions are subject to periodic review by the federal and state taxing authorities and management believes that the Fund continues to satisfy all federal and state statutes in order to qualify for continued tax exemption status. Part XI, Line 2d: Other revenue amounts included in F/S but not included on form 990 Special Events expenses $939042 Change in value of long-term pledges rec $256199 Part XII, Line 2d: Other expenses and losses per audited F/S Special Events expenses $939042 true Canada 0 0 Program grant Support for cancer research 34514 34514 34514 Canada Cancer research 34514 cash transfr 1 false false false false false false Part I, Line 2 - Grantmakers Explanation For Monitoring Use of Funds Outside US Once grants are approved, recipient organization must acknowledge the terms of the grant and reporting schedule. A budget is prepared in advance of all international grants. Financial and Narrative Reports are required at least once at the end of the project period. Expenditures are made in accordance with approved grant disbursements by the Board of Directors. Discussions, e-mails, and other techniques of communication are employed to ensure that funds are utilized according to the original intent. Accomplishments are documented in writing and submitted to the organization's head office. Part I, Line 3f - Method of Accounting Cash basis method of accounting is utilized. X X X X X false Canary Bike Events 1224141 37300 1186841 68675 60493 761181 Ladies Lunch 100265 100265 11922 29268 2 24625 24625 3328 4175 1349031 37300 1311731 80597 63821 794624 939042 372689 true Beth Israel Deaconess Medical 330 Brookline Avenue Boston MA 02215 042103881 56768 0 Cancer Research Seattle Inst Biomedical Clinical 1660 S Columbian Way S-151F Seattle WA 98108 911452438 31538 0 Cancer Research Stanford School Of Medicine 291 Campus Drive Stanford CA 94305 946174066 5300 0 Cancer Research Stanford University 450 Serra Mall Stanford CA 94305 946174066 5000000 0 Cancer Research UCSF Foundation 500 Parnassus MU-200W Box 0244 San Francisco CA 94143 942829914 59944 0 Cancer Research University of Michigan 648 N Shaw Lane Room East Lansing MI 48824 381358000 29128 0 Cancer Research University of Texas Health Ct 7703 Floyd Curl Drive San Antonio CA 78229 237232618 68744 0 Cancer Research University of Washington 1959 NE Pacific Seattle WA 98195 943079432 102520 0 Cancer Research Urology of Virginia 225 Clearfield Avenue Virginia Beach VA 23462 53006 0 Cancer Research 9 0 Grantmaker's Description of How Grants are Used The Canary Fund requires ongoing feedback in the form or oral and written reports in order to monitor the progress of each grant funded for approval. X X X X false false false false false false false false false false Ronica Smucker Exec Director 220000 29631 249631 Therese Quinlan Snr Developmt Dir 144000 15503 159503 X 3 320042 FMV X 1 74551 FMV X Bike Event 1132 51503 FMV false false false Form 990, Part III, Line 4d: Other Program Services Description OTHER PROGRAM SERVICES 4: CANARY OVARIAN CANCER PROGRAM(continued from Form 990 Page 2)biomarker discovery followed by validation, but they also involve different techniques and challenges.CANARY LUNG CANCER PROGRAMCanary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed. We plan to follow up on our research by rapidly propelling effective early detection cancer tests into the hands of clinical providers so that patients can begin to benefit as soon as possible. The Canary Lung Cancer Program supports the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening. OTHER PROGRAM SERVICES 5: CANARY PROSTATE CANCER PROGRAMThe specific goals of the Canary Foundation Prostate program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but unvalidated candidate markers for prostate cancer, we are focusing our initial efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on their ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We are focusing on blood-based biomarkers for early detection and considering both blood-based and tissue-based biomarkers for prognostic applications. OTHER PROGRAM SERVICES 6: CANARY PANCREATIC CANCER PROGRAMCanary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal pancreatic cancers at an early stage when they can be cured through surgical section. We anticipate that no single biomarker will be sufficient to create a test with the required sensitivity and specificity to detect pancreatic cancer early. Instead, a definitive diagnosis will rely upon combinations of biomarkers and upon blood and imaging tests used together. To this end, the Canary pancreatic cancer team is collaborating to discover and validate biomarkers that will provide the basis for blood and imaging tests for the early detection of pancreatic cancer. We plan to follow up our research by rapidly propelling effective early detection tests into the hands of clinical providers to that patients can begin to benefit as soon as possible. OTHER PROGRAM SERVICES 7: CANARY COLLABORATIONS PROGRAMCanary Foundation believes that a collaborative, coordinated approach is necessary to achieve our goals. Our multi-disciplinary, multi-institutional Early Detection Program provides a great example of this philosophy in action. We created our Collaboration Program to foster this collaborative approach among the broader community of cancer researchers. We provide scientific program management to make sure that all funded research activities among the scientists and clinicians at the various partner institutions are on track and that any obstacles are rapidly addressed and overcome. The specific collaboration programs that we support include: national and international workshops and symposiums, a postdoctoral training program, an online scientific journal, and joint projects with government and foundations. OTHER PROGRAM SERVICES 8: CANARY CENTER AT STANFORD FOR CANCER EARLY DETECTIONOn September 13, 2008, together with Dr. Bev Mitchell, Director of Stanford's Cancer Institute, and Dr. Sanjiv (Sam) Gambhir, Director of Stanford's Molecular Imaging Programs (MIPS), Canary Foundation announced the creation of the Canary Center at Stanford. The Canary Center at Stanford is the only facility in the world with dedicated full-time faculty focused on the cancer early detection and integrates both blood and imaging-based diagnostic research. This first class integrated facility attracts and develops the best minds in the world to the problem of cancer early detection. Operations commenced in the spring of 2009.The Canary Center at Stanford operates in a 33,000-square-foot facility at Stanfords Technology and Innovation Park in Palo Alto. The Center houses multiple faculty devoted to early detection of cancer and over 100 research affiliates. Dr. Sanjiv (Sam) Gambhir, chair of Radiology at Stanford, leads the Center as Scientific Director. The Center is supported by research "cores" that provide scientific capabilities to the research teams. The four initial cores are Chemistry, Proteomics, Bioinformatics, and Clinical Trials.The Canary Center at Stanford brings together multiple stakeholders, including the School of Medicine, the Radiology Department, the Stanford Cancer Institute, and Canary Foundation. Initially, Canary Foundation dedicated $25 million for start-up costs, including equipment, modest renovations to the existing research facility, staffing, and faculty recruitment. The Department of Radiology committed to four new faculty members in molecular imaging, as well as $4 million to support faculty recruitment. The School of Medicine committed to four new faculty members for the Center and has committed to supporting the research programs. Four of the eight faculty positions have been filled.A Complete discussion of all of The Canary Foundation's program activities is provided below and continues on Schedule O. Total Expenditures Related to Program Activities amounted to $6,000,378. Form 990, Part VI, Line 1a: Explanation of Delegated Broad Authority to Committee In accordance with common practice in the nonprofit community, the Board delegates certain matters to The Executive Committee, which is empowered to act between board meetings if necessary, and sometimes with specifically delegated authority to act in particular areas on behalf of the full board. Form 990, Part VI, Line 2: Description of Business or Family Relationship of Officers, Directors, Et Board members Don Listwin (President) and Hilary Valentine (Director) are related to each other as husband and wife. Board member Don Listwin sits on the Board of directors of fellow board member Michael Ball's company. Form 990, Part VI, Line 11b: Form 990 Review Process FORM 990 IS PREPARED BY AN OUTSIDE TAX PROFESSIONAL. THE FORM IS THEN REVIEWED BYTHE ORGANIZATION'S MANAGEMENT AND A MEMBER OF THE BOARD OF DIRECTORS. THIS GROUP OF INDIVIDUALS THEN DISCUSSES THE CONTENTS OF THE RETURN WITH THE OUTSIDE TAX PROFESSIONAL. AFTER A FULL REVIEW (WITH MODIFICATIONS WHERE NECESSARY), THE FINAL VERSION OF THE TAX RETURN IS PROVIDED TO ALL MEMBERS OF THE ORGANIZATION'S VOTING BODY. A REPRESENTATIVE OF MANAGEMENT AUTHORIZES THE FINAL FORM 990 WHICH IS THEN E-FILED WITH THE INTERNAL REVENUE SERVICE. Form 990, Part VI, Line 12c: Explanation of Monitoring and Enforcement of Conflicts MEMBERS OF THE BOARD OF DIRECTORS REVIEW ALL POTENTIAL CONFLICTS OF INTEREST ATLEAST ANNUALLY. THE EXECUTIVE DIRECTOR AND ALL BOARD MEMBERS ARE REQUIRED TO DISCLOSE (IN WRITING) POTENTIAL CONFLICTS AND ANY RELATED PARTY AFFILIATIONS. LOANS BETWEEN THE ORGANIZATION AND MEMBERS OF MANAGEMENT AND THE BOARD ARE STRICTLY PROHIBITED. THE ORGANIZATION SEEKS FULL TRANSPARENCY ON ALL RELATIONSHIPS. ANY POTENTIAL CONFLICTS (IN FACT OR APPEARANCE) ARE DISCUSSED OPENLY AND RESOLVED IN ACCORDANCE WITH THE ORGANIZATION'S POLICIES AND PROCEDURES. Form 990, Part VI, Line 15a: Compensation Review & Approval Process - CEO, Top Management MEMBERS OF THE BOARD OF DIRECTORS REVIEW THE COMPENSATION OF ALL HIGH-LEVEL PERSONNEL PERIODICALLY IN ACCORDANCE WITH IRS RULES AND REGULATIONS. EFFORTS ARE MADE TO SECURE COMPENSATION DATA FROM INDUSTRY SOURCES IN ORDER TO DETERMINE COMPETITIVENESS AND APPROPRIATENESS OF SALARIES. EVERY EFFORT IS MADE TO ENSURE THAT THE PROCESS IS THOROUGH AND TRANSPARENT IN ACCORDANCE WITH IRS GUIDELINES AND THE ORGANIZATION'S POLICIES AND PROCEDURES. Form 990, Part VI, Line 15b: Compensation Review and Approval Process for Officers and Key Employees COMPENSATION OF OTHER HIGH-LEVEL PERSONNEL AND KEY EMPLOYEES IS REVIEWED PERIODICALLY BY MEMBERS OF MANAGEMENT. EFFORTS ARE MADE TO SECURE COMPENSATION DATA FROM INDUSTRY SOURCES IN ORDER TO DETERMINE COMPETITIVENESS AND APPROPRIATENESS OF SALARIES AND ALL RELATED BENEFITS. ALL DECISIONS ARE THEN DOCUMENTED IN PERSONNEL FILES. Form 990, Part VI, Line 19: Other Organization Documents Publicly Available ALL OF THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS AND OTHER LEGALFILINGS ARE MAINTAINED IN A SECURE ENVIRONMENT AND HELD AVAILABLE FOR INSPECTION BYTAX AUTHORITIES AND THE GENERAL PUBLIC. TAX RETURNS ARE POSTED ANNUALLY TOWWW.GUIDESTAR.ORG (WHERE IT IS AVAILABLE FOR VIEWING AS AN ELECTRONIC COPY) AND ARE ALSO AVAILABLE FOR A PHYSICAL INSPECTION AT THE ORGANIZATION'S OFFICE IN Redwood City, CALIFORNIA. Other Changes In Net Assets Or Fund Balances - Other Increases Change in value of long-term pledges receivable = $256199